{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05818683",
            "orgStudyIdInfo": {
                "id": "CR109321"
            },
            "secondaryIdInfos": [
                {
                    "id": "78278343PCR1003",
                    "type": "OTHER",
                    "domain": "Janssen Research & Development, LLC"
                }
            ],
            "organization": {
                "fullName": "Janssen Research & Development, LLC",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer",
            "officialTitle": "A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Castration-Resistant Prostate Cancer",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-jnj-in-combination-with-either-jnj-cetrelimab-taxane-chemotherapy-or-androgen-receptor-pathway-inhibitors-for-metastatic-castration-resistant-prostate-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-04-26",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-09-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-04-06",
            "studyFirstSubmitQcDate": "2023-04-06",
            "studyFirstPostDateStruct": {
                "date": "2023-04-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Janssen Research & Development, LLC",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of JNJ-78278343 and combination agent in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of JNJ-78278343 with the combination agent in Part 2 (dose expansion)."
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Castration-resistant Prostate Neoplasms"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 345,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "JNJ-78278343 + Combination agent: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive JNJ-78278343 and combination agent (cetrelimab, cabazitaxel, docetaxel, apalutamide, enzalutamide, Darolutamide, abiraterone acetate plus prednisone) during Part 1 (dose escalation). The dose of JNJ-78278343 will be escalated sequentially until a recommended phase 2 regimen (RP2R). Participants will receive JNJ-78278343 and combination agent treatment at the putative RP2R in Part 2 (dose expansion).",
                    "interventionNames": [
                        "Drug: JNJ-78278343",
                        "Drug: Cetrelimab",
                        "Drug: Cabazitaxel",
                        "Drug: Docetaxel",
                        "Drug: Apalutamide",
                        "Drug: Enzalutamide",
                        "Drug: Darolutamide",
                        "Drug: Abiraterone acetate plus prednisone (AAP)"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "JNJ-78278343",
                    "description": "JNJ-78278343 will be administered.",
                    "armGroupLabels": [
                        "JNJ-78278343 + Combination agent: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cetrelimab",
                    "description": "Cetrelimab will be administered by intravenous infusion.",
                    "armGroupLabels": [
                        "JNJ-78278343 + Combination agent: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)"
                    ],
                    "otherNames": [
                        "JNJ-63723283"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cabazitaxel",
                    "description": "Cabazitaxel will be administered by intravenous infusion.",
                    "armGroupLabels": [
                        "JNJ-78278343 + Combination agent: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Docetaxel",
                    "description": "Docetaxel will be administered by intravenous infusion.",
                    "armGroupLabels": [
                        "JNJ-78278343 + Combination agent: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Apalutamide",
                    "description": "Apalutamide will be administered orally.",
                    "armGroupLabels": [
                        "JNJ-78278343 + Combination agent: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Enzalutamide",
                    "description": "Enzalutamide will be administered orally.",
                    "armGroupLabels": [
                        "JNJ-78278343 + Combination agent: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Darolutamide",
                    "description": "Darolutamide will be administered orally.",
                    "armGroupLabels": [
                        "JNJ-78278343 + Combination agent: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Abiraterone acetate plus prednisone (AAP)",
                    "description": "Abiraterone acetate plus prednisone (AAP) will be administered orally.",
                    "armGroupLabels": [
                        "JNJ-78278343 + Combination agent: Part 1 (Dose Escalation) and Part 2 (Dose Expansion)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Part 1: Number of Participants With Dose Limiting Toxicity (DLT)",
                    "description": "DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity or hematologic toxicity.",
                    "timeFrame": "Up to 21 days after first dose of combination agent"
                },
                {
                    "measure": "Part 1 and Part 2: Number of Participants with Adverse Events (AEs) by Severity",
                    "description": "An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 with the exception of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome events, which will be graded by American Society for Transplantation and Cellular Therapy (ASTCT) guidelines. Severity scale ranges from grade 1 (mild) to grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse event.",
                    "timeFrame": "Up to 2 years 11 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Overall Response Rate (ORR)",
                    "description": "ORR is defined as the percentage of participants who have a partial response (PR) or better without evidence of bone progression according to Prostate Cancer Working Group 3 (PCWG3) criteria.",
                    "timeFrame": "Up to 2 years 11 months"
                },
                {
                    "measure": "Prostate Specific Antigen (PSA) Response Rate",
                    "description": "PSA response rate is defined as the percentage of participants with a confirmed decline of PSA of 50 percent (%) or more from baseline.",
                    "timeFrame": "Up to 2 years 11 months"
                },
                {
                    "measure": "Radiographic Progression-free Survival (rPFS)",
                    "description": "rPFS is defined time from the date of first dose of JNJ-78278343 until the date of objective disease progression or death, whichever comes first.",
                    "timeFrame": "Up to 2 years 11 months"
                },
                {
                    "measure": "Time to Response (TTR)",
                    "description": "TTR is defined for the responders as the time from the date of first dose of to the date of first documented response that is subsequently confirmed.",
                    "timeFrame": "Up to 2 years 11 months"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "description": "DOR is defined for participants who achieved response (PR or better) as the time between the date of initial documentation of response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3, or death due to any cause, whichever occurs first.",
                    "timeFrame": "Up to 2 years 11 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Metastatic castration-resistant prostate cancer (mCRPC) with confirmed adenocarcinoma of the prostate as defined by Prostate Cancer Working Group 3 (PCWG3)\n* Measurable or evaluable disease.\n* (a) Part 1A: JNJ-78278343 + cetrelimab - Prior treatment for mCRPC with at least 1 prior androgen receptor pathway inhibitors (ARPI) (that is, abiraterone acetate, apalutamide, enzalutamide, darolutamide), or chemotherapy (eg, docetaxel). (b) Part 1C: JNJ-78278343 + docetaxel, Part 1D: JNJ-78278343 + apalutamide, Part 1E: JNJ-78278343 + enzalutamide, Part 1F: JNJ-78278343 + darolutamide, and Part 1G: JNJ-78278343 + abiraterone acetate + prednisone - Prior treatment with at least 1 prior ARPI (that is, apalutamide, enzalutamide, darolutamide, or abiraterone acetate,). (C) Part 1B: JNJ-78278343 + cabazitaxel - Prior treatment with at least 1 prior ARPI (ie, abiraterone acetate, apalutamide, enzalutamide, darolutamide) and docetaxel.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Adequate organ functions\n\nExclusion Criteria:\n\n* Active autoimmune disease within the 12 months prior to signing consent that requires systemic immunosuppressive medications\n* Toxicity related to prior anticancer therapy that has not returned to Grade less than or equal to (\\<=) 1 or baseline levels (except for alopecia, vitiligo, Grade \\<=2 peripheral neuropathy)\n* Solid organ or bone marrow transplantation\n* Known allergies, or intolerance to any of the components (example, excipients) of JNJ-78278343, cetrelimab (Part 1A), cabazitaxel, (Part 1B), docetaxel (Part 1C), apalutamide (Part 1D), enzalutamide (Part 1E), darolutamide (Part 1F), or abiraterone acetate + prednisone (AAP) (Part 1G)\n* Significant infections or serious lung, heart or other medical conditions",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Study Contact",
                    "role": "CONTACT",
                    "phone": "844-434-4210",
                    "email": "Participate-In-This-Study@its.jnj.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Janssen Research & Development, LLC Clinical Trial",
                    "affiliation": "Janssen Research & Development, LLC",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Florida Cancer Specialists",
                    "status": "RECRUITING",
                    "city": "Sarasota",
                    "state": "Florida",
                    "zip": "34232",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 27.33643,
                        "lon": -82.53065
                    }
                },
                {
                    "facility": "Start Midwest",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49546",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "Macquarie University",
                    "status": "RECRUITING",
                    "city": "Macquarie University",
                    "zip": "2109",
                    "country": "Australia"
                },
                {
                    "facility": "Peter MacCallum Cancer Centre",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "zip": "3000",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                },
                {
                    "facility": "Princess Alexandra Hospital",
                    "status": "RECRUITING",
                    "city": "Woolloongabba",
                    "zip": "4102",
                    "country": "Australia",
                    "geoPoint": {
                        "lat": -27.48855,
                        "lon": 153.03655
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu",
            "url": "https://www.janssen.com/clinical-trials/transparency"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30",
            "removedCountries": [
                "Korea, Republic of"
            ]
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Neoplasm",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3215",
                    "name": "Kennedy Disease",
                    "asFound": "Androgen Receptor",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011241",
                    "term": "Prednisone"
                },
                {
                    "id": "D000077143",
                    "term": "Docetaxel"
                },
                {
                    "id": "D000069501",
                    "term": "Abiraterone Acetate"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000065088",
                    "term": "Steroid Synthesis Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000065607",
                    "term": "Cytochrome P-450 Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14121",
                    "name": "Prednisone",
                    "asFound": "Prospective",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1668",
                    "name": "Docetaxel",
                    "asFound": "Management",
                    "relevance": "HIGH"
                },
                {
                    "id": "M451",
                    "name": "Abiraterone Acetate",
                    "asFound": "Unilateral",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4059",
                    "name": "Androgens",
                    "relevance": "LOW"
                },
                {
                    "id": "M147959",
                    "name": "Taxane",
                    "relevance": "LOW"
                },
                {
                    "id": "M10638",
                    "name": "Kallikreins",
                    "relevance": "LOW"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M30537",
                    "name": "Cytochrome P-450 Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Coag",
                    "name": "Coagulants"
                },
                {
                    "abbrev": "Repr",
                    "name": "Reproductive Control Agents"
                }
            ]
        }
    },
    "hasResults": false
}